Nasdaq
$3.16▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $465.7MShares out 1.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 2d agoPre-market26.10.23 19:1920-FEarnings#●●●#●●●#●●●
IMMUTEP LtdBullish
Immutep entered into an exclusive license agreement with Dr. Reddy's Laboratories on December 8, 2025, for its proprietary oncology product candidate, 'Efti' (eftilagimod alfa). Under this agreement, Dr. Reddy's is granted exclusive rights to develop, register, market, and sell the product within the defined territory.…more
$3.16+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Pre-market26.10.14 10:07filed6-KKey event
IMMUTEP Ltd
Immutep has regained compliance with the Nasdaq minimum bid price requirement. The company received confirmation from Nasdaq that the matter is closed after its ADS closing bid price remained at or above $1.00 for 10 consecutive business days from September 28 to October 9, 2026.…more
$3.16+0.00%vs prev closeView filingShare - 9.22Pre-market26.09.22 19:016-KKey event
IMMUTEP Ltd
Immutep will change its ADS ratio from 1:10 to 1:200 effective September 28, 2026, to regain compliance with the Nasdaq minimum bid price requirement. This action has the practical effect of a 1-for-20 reverse split for ADS holders, while the total number of ordinary shares and the company's capital structure remain unchanged.…more
$3.16+0.00%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 21:00#●●●#●●●
Immutep Presents Quality of Life Data from EFTISARC-NEO Phase II Trial
Immutep announced that patients in its Phase II soft tissue sarcoma trial maintained stable quality of life during treatment, with significant improvements reported post-surgery. While presented at ESMO 2026, the data remains a clinical update without immediate commercial impact, warranting a neutral outlook.…more
$3.16+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 2d agoPre-market26.10.23 21:02
●●●●●●●● ●●●●● ●●●●●●
Immutep announced health-related quality of life data from its Phase II EFTISARC-NEO trial evaluating eftilagimod alfa in combination with KEYTRUDA for soft tissue sarcoma. This follows previously reported positive primary endpoint results where the combination significantly exceeded tumor fibrosis targets.…more
$3.16+0.00%vs prev closeShareBenzinga - 6d agoPre-market26.10.19 21:05
●●●●●●●● ●●●●● ●●●●●●
Immutep's abstract for its first-in-human Phase 1 study of IMP761 has been accepted for a poster presentation at ACR Convergence 2026. The presentation will highlight data from the study conducted on healthy volunteers.…more
$3.16+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report